Prestige Biopharma eyes complete value chain
BARCELONA, Spain – Prestige Biopharma, a Kospi-listed biopharmaceutical firm based in Singapore, said Tuesday it is seeking to complete its value chain of new drug development with its upcoming research center in Busan.
“Prestige Biopharma’s research and development of antibody drugs will pick up speed after the company opens its new research center in Busan,” Prestige Biopharma Chairman Park So-yeon told reporters at the Convention on Pharmaceutical Ingredients (CPHI) Worldwide 2023, the world’s largest pharma trade show that kicked off earlier this week in Barcelona, Spain.
The new plant, called Innovative Discovery Center or IDC, is currently under construction on a 31,000 square-meter site in the southern port city, with plans for completion by May next year. A total of $152 million has been injected into the construction.
With the completion, the firm’s main R&D unit will be relocated to the new facility. In line with the relocation, its staff members are also expected to surge from the current 55 to some 200 by 2030.
Currently, the firm’s Singapore headquarters is responsible for overseeing clinical trials and regulatory approval of new drugs, while its plant in Osong, North Chungcheong Province, is responsible for contract manufacturing.
Park stressed that the new Busan R&D center will play a key role in completing its value chain encompassing research, development and production of new antibody drugs.
She added the new facility will share floor space with its open innovation partners, including medical schools in the region.
"Open innovation will allow the company to speed up its research and development of new antibody drugs and reduce costs," Park said.
“When the new center is completed, we plan to invite officials from our partner firms, including the CancerX project. The center will become a global hub for new drug development.”
Cancer X is a public-private partnership program part of the Biden administration’s Cancer Moonshot Project. Prestige Biopharma also joined the program in July.
Currently, the company is waiting for regulatory approval for its biosimilars, including its Herceptin biosimilar HD201 and Humira biosimilar PBP1502. For the HD201, the firm has signed a license-out deal with four global partners.
(责任编辑:건강)
- Criminal procedures for foreigners in Korea
- LG CNS launches new AI platform for corporate clients
- The ruling party vows extraordinary measures to win back people's trust after crushing by
- [Herald Interview] Monte
- School violence drops, drugs among teens surge: police
- 문 정부, 셀트리온에 코로나 R&D 예산 522억 몰아줬다
- Art Busan's unveils galleries, theme for inaugural fair, Define Seoul
- Pentagon chief stresses US ability to tackle 'crises in multiple theaters'
- Trilateral cooperation unaffected by US election outcomes: Goldberg
- [HIT Forum] Sci
- S. Korea warns of potential NK surprise attacks using Hamas tactics
- Viviz to drop 4th EP ‘Versus’ next month
- Volvo EX30 debuts in Korea
- [Korean History] In 2003's Daegu, disaster plays out underground
- 'Do not open plane doors' warning mandated for planes in flight
- The 2023 Seoul Fantastic Beer Festival
- [New on scene] Kim Chang
- The 2023 Seoul Fantastic Beer Festival
- Seoul anticipates 3
- PM makes official visit to Denmark to promote Expo bid
- [Korea Quiz] Lucrative MLB careers views+
- Floor leader of main opposition party voices disappointment at Yoon's budget speech views+
- US lawmaker submits bill requiring Pentagon report on allies' defense contribution views+
- Director touts Netflix's ‘Daily Dose of Sunshine’ as warm tale for adults views+
- AmCham reaffirms Korea views+
- HDC to spur digital innovation for efficiency, safety views+
- FM Park, Blinken to meet in Seoul next week views+
- 협치 첫 단추 ‘현수막 난립방지법’ 소위 통과 views+
- Memorial park for independence fighter to open in Kazakhstan views+
- [Korea Beyond Korea] From history and K views+